preprint
A clinical trial involving 600 participants evaluated the antiparasitic drug ivermectin alongside standard care for treating and preventing COVID-19, comparing it with hydroxychloroquine regimens. Among 400 symptomatic patients, individuals with mild or moderate disease who received ivermectin achieved a 99 per cent improvement rate and zero mortality, compared to 74 per cent improvement and four per cent mortality for those on hydroxychloroquine. In severe cases, the ivermectin group recorded a 94 per cent improvement rate and two per cent mortality, whereas the hydroxychloroquine group experienced 50 per cent improvement and 20 per cent mortality. Furthermore, ivermectin treatment correlated with quicker RT-PCR viral clearance and improved laboratory markers. Among 200 healthcare workers and household contacts, preventative use of ivermectin alongside personal protective equipment reduced the infection rate to two per cent, compared to ten per cent when using protective equipment alone.
Effective and accessible therapies are critical for managing COVID-19 infections and protecting vulnerable healthcare workers and household contacts. Demonstrating that an existing, affordable medication could reduce mortality in severe cases, accelerate recovery, and provide protective benefits against transmission highlights potential pathways to alleviate hospital burdens and enhance clinical outcomes during pandemic surges.
This research tests the repurposing of an established medication in clinical settings, demonstrating applied clinical evaluation across therapeutic and preventative treatment regimens. Healthcare providers, hospital systems, and public health authorities could potentially adopt these protocols for COVID-19 management. Because the tested substance is an already existing pharmaceutical, implementation would depend on clinical adoption and regulatory endorsement of new treatment protocols rather than novel drug manufacturing.
AI-generated from the published abstract. Always read the original work before citing.
<title>Abstract</title> <bold>Background:</bold> Up-to-date, there is no recognized effective treatment or vaccine for the treatment of COVID-19 that emphasize urgency around distinctive effective therapies. This study aims to evaluate the anti-parasitic medication efficacy "Ivermectin" plus standard care ((Azithromycin, vitamin C, Zinc, Lactoferrin & Acetylcystein & prophylactic or therapeutic anticoagulation if D-dimer > 1000)) in the treatment of mild/moderate and severely ill cases with COVID 19 infection, as well as prophylaxis of health care and/ or household contacts in comparison to the <italic>Hydroxychloroquine</italic> plus standard treatment. <bold>Subject and methods:</bold> 600 subjects; 400 symptomatic confirmed COVID-19 patients and 200 health care and household contacts distributed over 6 groups; <italic>Group I</italic> <bold>:</bold> 100 patients with mild/moderate COVID-19 infection received a 4-days course of Ivermectin plus standard of care; <italic>Group II:</italic> 100 patients with mild/moderate COVID-19 infection received hydroxychloroquine plus standard of care; <italic>Group III:</italic> 100 patients with severe COVID-19 infection received Ivermectin plus standard of care; <italic>Group IV</italic> : 100 patients with Severe COVID-19 infection received hydroxychloroquine plus standard of care. Routine laboratory investigations and RT-PCR, were reported before and after initiation of treatment. <italic>Group V stick to PPE plus Ivermectin 400mcg / kg on empty stomach to be repeated after one week, and group VI stick to PPE only (personal protective equipment) .Both groups V&VI were followed for two weeks ..</italic> <bold>Results:</bold> Patients received ivermectin reported substantial recovery of laboratory investigations; and significant reduction in RT-PCR conversion days. A substantial improvement and reduction in mortality rate in Ivermectin treated groups; group I (mild/moderate cases), (99%, and 0.0%, respectively) and group III (severe cases), (94%, and 2.0% respectively) versus hydroxychloroquine plus standard care treated groups; group II (mild/moderate cases), (74% and 4%, respectively) and group IV (severe cases) (50% and 20%, respectively). Ivermectin had significantly reduced the incidence of infection in health care and household contacts up to 2% compared to 10% in non ivermectin group when used as a prophylaxis. <bold>Conclusion:</bold> <italic/> Addition of Ivermectin to standard care is very effective drug for treatment of COVID-19 patients with significant reduction in mortality compared to Hydroxychloroquine plus standard treatment only. Early use of Ivermectin is very useful for controlling COVID 19 infections; prophylaxis and improving cytokines storm
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.21203/rs.3.rs-100956/v2
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
